The National Medicines Safety Agency (ANSM) on Friday authorized the use of ronaprev treatment against Kovid-19. “We are expanding the use of dual monoclonal antibody therapy Kasirivimab / Imdevimab,” the company said in a statement.
Ronaprev, treatment for it Kovid-19 Synthetic antibodies, which until then had been specialized for the prevention of the disease and the fight against its early forms, were also authorized on Friday in France in a more advanced stage in patients already hospitalized. “By September 3, 2021, we are expanding the use of dual monoclonal antibody therapy kasirivimab / imdevimab, depending on the identified medical need for the management of patients in the advanced stage of Kovid-19 disease,” the press release said. National Medicines Safety Agency (ANSM).
This treatment, marketed under the name Ronaprev by the American laboratory Regeneran, is already authorized to protect against early forms of the disease in high-risk individuals and to prevent them from appearing immunocompromised. It is now given in more advanced stages, in patients already hospitalized and at risk of developing a severe form. “This applies to patients who are not immunocompromised, at risk for complications related to comorbidities, patients aged 80 and over,” ANSM explained.
One of the main treatment options
This treatment is reserved for so-called non-invasive oxygen therapy, which excludes special intubations if they do not develop antibodies against the disease. Synthetic antibody treatments are one of the main therapies against Kovid-19, but so far they have been prescribed as a cure or shortly after the onset of symptoms.
Shortly before the summer, as part of a larger European clinical trial recovery, patients already admitted to the hospital reported positive results by Ronaprev. Some scientists have qualified these results, however, pointing out that treatment can only prevent a limited number of deaths.